Liminatus Pharma, Inc.

NasdaqGM:LIMN Stock Report

Market Cap: US$6.2m

Liminatus Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LIMN?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,492,2093.33%
Public Companies1,500,0003.34%
Private Companies5,196,66711.6%
Individual Insiders9,109,40620.3%
General Public27,579,35161.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 72.5%.

Top Shareholders

Top 22 shareholders own 38.55% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.8%
Chris Kim
6,169,406US$848.3k0%no data
5.94%
KH Feelux Co., Ltd.
2,666,667US$366.7k-33.3%no data
5.64%
Columbass Limited
2,530,000US$347.9k-63.3%no data
3.34%
HMNEX Co., Ltd.
1,500,000US$206.2k0%no data
3.28%
Kyung Hyun
1,470,000US$202.1k0%no data
3.28%
Mary Song
1,470,000US$202.1k0%no data
1.51%
Citadel Advisors LLC
677,518US$93.2k855%no data
0.78%
Cygnus Capital Advisors, LLC
350,000US$48.1k0%0.04%
0.26%
Geode Capital Management, LLC
117,783US$16.2k81.1%no data
0.16%
Jane Street Group, LLC
71,318US$9.8k0%no data
0.12%
UBS Asset Management AG
54,578US$7.5k181%no data
0.11%
Vanguard Capital Management, LLC
50,440US$6.9k0%no data
0.077%
Vanguard Personalized Indexing Management
34,706US$4.8k0%no data
0.061%
Virtu Financial, Inc.
27,468US$3.8k0%no data
0.051%
Vanguard Fiduciary Trust Company
22,984US$3.2k0%no data
0.049%
Two Sigma Securities, LLC
22,039US$3.0k85.6%no data
0.042%
State Street Global Advisors, Inc.
19,000US$2.6k0%no data
0.037%
FMR LLC
16,771US$2.3k0.01%no data
0.03%
BlackRock, Inc.
13,254US$1.8k-0.01%no data
0.017%
Tower Research Capital Europe Limited
7,567US$1.0k-15%no data
0.015%
Citigroup Inc.
6,769US$930.5677,000%no data
0.00003%
Farther Finance Advisors, LLC
14US$1.9-54.8%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 07:19
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Liminatus Pharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.